The predictive significance of CD20 expression in B-cell lymphomas.
about
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups.Combination strategies to enhance antitumor ADCC.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Phenotypic characterization of trisomy 12 monoclonal B-cell lymphocytosis.NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma.
P2860
Q33626106-BFD6AE2C-D598-474F-B3E9-BEEFFADDDDA1Q35760142-A0DB6161-5E74-4E67-AC8A-52DC7CE1EE0BQ36161443-FA45EEE1-C592-45DE-BCA6-04E2816365B4Q37079029-4D888DF2-285F-4D06-8769-A3E78579E88DQ37369563-A31AD1E0-5914-4A9A-BA2C-9E447CC661A7Q38014085-8C414D2A-672F-40A2-AA0A-372155028E30Q38126946-B02432A4-5C29-4B54-8165-EB883BBA161AQ38445357-1BA358AB-C83F-4835-8732-166DBD8C366FQ38694867-566B6404-D505-42F9-869C-FC04AC729DFDQ39004366-ADC933EB-B4A3-4EAD-8D3F-8350E5D75FE0Q48697787-CEE13058-AEB3-4697-9A63-5A3ABB6F6BB6Q51543249-9E0E78D9-BFE7-4281-85EA-111607C9AEAFQ53758334-EE94CF61-A688-4F3F-9B4E-F89CF3189D7CQ54998752-8FD4A440-E6AD-4102-9383-F37EDC774898
P2860
The predictive significance of CD20 expression in B-cell lymphomas.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The predictive significance of CD20 expression in B-cell lymphomas.
@ast
The predictive significance of CD20 expression in B-cell lymphomas.
@en
The predictive significance of CD20 expression in B-cell lymphomas.
@nl
type
label
The predictive significance of CD20 expression in B-cell lymphomas.
@ast
The predictive significance of CD20 expression in B-cell lymphomas.
@en
The predictive significance of CD20 expression in B-cell lymphomas.
@nl
prefLabel
The predictive significance of CD20 expression in B-cell lymphomas.
@ast
The predictive significance of CD20 expression in B-cell lymphomas.
@en
The predictive significance of CD20 expression in B-cell lymphomas.
@nl
P2093
P2860
P356
P1433
P1476
The predictive significance of CD20 expression in B-cell lymphomas.
@en
P2093
Barbara Jezeršek Novakovič
Jaka Lavrenčak
Mateja Horvat
Veronika Kloboves Prevodnik
P2860
P2888
P356
10.1186/1746-1596-6-33
P577
2011-04-12T00:00:00Z
P5875
P6179
1047691962